Physician profile
Donna Delfin
NPI 1477718740
$7,192.94
in general payments reported to CMS, 2019-2025
49 companies · $1,083 in 2025
The $1,083 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,284 · 2020: $350 · 2021: $211 · 2022: $582 · 2023: $1,254 · 2024: $2,429 · 2025: $1,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,766.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,184.97 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $1,008.28 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $698.62 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $485.80 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $362.44 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $309.94 | 2019-2025 | Jardiance |
| Corium, LLC | $239.33 | 2022-2024 | Azstarys |
| Astellas Pharma US INC | $205.40 | 2019-2025 | Veozah, Myrbetriq |
| Amgen INC. | $204.41 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $199.60 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Eisai INC. | $198.93 | 2019-2025 | |
| Bausch Health US, LLC | $155.43 | 2022-2025 | Aplenzin, Wellbutrin |
| Axsome Therapeutics, INC. | $140.05 | 2024 | Sunosi |
| Janssen Pharmaceuticals, INC | $131.36 | 2019 | |
| Tactile Systems Technology INC | $121.87 | 2019 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Delfin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.